Grove was launched on 1 March 2023. Swansea University assigned 3 patents to Grove, and provided 2 years of free lab access, for a 20% shareholding.

Grove’s first financial investors (Spring 2023) were two Angel investors, former students of the Founder, who together contributed £67.5k. They were soon joined by Deepbridge Corporation, led by Andy Round, with a first SEIS investment of £150k.

In 2024, Grove obtained a second phase of pre-seed funding, from the Development Bank of Wales (led by Linzi Plant), £150k, and a second SEIS investment by Deepbridge, £100k. This total of £250k was matched by a grant from the Innovate UK investor-partnership scheme, £210k. Moreover in 2024 Grove also won substantial grants from the Welsh Government, through the Smart-FIS scheme, totalling £225k.

In 2025, Grove has been further boosted by an Acceleration round of further pre-seed Angel funding, £125k. This brings total commercial investment to date to almost £600k, alongside more than £400k of grants, so total funding now exceeds £1million.  

As of June 2025, Grove has demonstrated the fabrication of red, green and blue colloidal gold nanoparticles, as well as their successful utilisation in lateral flow systems. Grove has also completed the proof of principle development of its first (home) lateral flow test, in the allergy sector, where Grove has accumulated notable expertise and collaborations. Three further tests are also in development. Grove moved into its own Lab in Cardiff (spark) in November 2024.

Grove’s initial product pipeline for lateral flow tests includes four more tests. These are critical tests for early-stage cancer and infection. Grove has established a strategic partnership with Cardiff University, to exploit point-of-care and home tests developed by its Professors.

The immediate commercial outlook is that the colloids fabricated by Grove’s new Nanofactory machine should go to market in the Winter of 2025/2026. ISO9001 quality approval is in progress. The first lateral flow test should be submitted to the regulatory process, also by Winter 2025/2026, with three further tests following in 2026.

The immediate investment outlook is that Grove seeks Seed Round investment in January 2026. The aim, on a 2-year runway, is to establish Grove as a flourishing, revenue-generating nano-materials and diagnostics business, with considerable potential for additional growth in, and beyond, the sector.